(Total Views: 928)
Posted On: 09/28/2020 5:42:55 PM
Post# of 154105
I can understand why most of the medical profession would be doubtful of leronlimab. Why would an HIV drug be effective outside of that indication? Unless they start digging into CCR5 research they won't know.
After initially buying some CYDY stock I had my doubts on cancer until I started digging down into it and found out how far reaching the activities of CCR5 were. Along the way I kept running into medical papers for CCR5 and other diseases and realized how much inflammation and autoimmunity were involved. I still had my doubts on brain related diseases until I realized it wasn't absolutely necessary for leronlimab to cross the blood brain barrier to have effect and then later on figured out it could cross the BBB.
But if I can figure it out then eventually the medical community will catch on. The easiest way for that to happen is massive exposure from COVID-19 approval.
After initially buying some CYDY stock I had my doubts on cancer until I started digging down into it and found out how far reaching the activities of CCR5 were. Along the way I kept running into medical papers for CCR5 and other diseases and realized how much inflammation and autoimmunity were involved. I still had my doubts on brain related diseases until I realized it wasn't absolutely necessary for leronlimab to cross the blood brain barrier to have effect and then later on figured out it could cross the BBB.
But if I can figure it out then eventually the medical community will catch on. The easiest way for that to happen is massive exposure from COVID-19 approval.
(20)
(0)
